Trial · NCT02383433
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
NCT02383433, Phase 2, Terminated, Case Comprehensive Cancer Center; results first posted 2019-05-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer. Trials, record NCT02383433. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02383433
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
- NCT number
- NCT02383433
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Case Comprehensive Cancer Center
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Regorafenib, Gemcitabine Hydrochloride
- First posted
- 2015-03-09
- Last updated
- 2023-10-23
- Results first posted
- 2019-05-10
- Limitations and caveats
- Data was not collected, study terminated early due to low accrual.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival | Up to 1 year from enrollment | Time-to-event data will be summarized using the Kaplan-Meier method. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival | Up to 1 year from enrollment | Data was not collected for this outcome, study terminated early due to low accrual. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 2 | |
| Overall Study | COMPLETED | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 0 | |
| Overall Study | NOT COMPLETED | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 2 |
Source ClinicalTrials.gov
Adverse events52
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Alkaline phosphatase increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 2 |
| other | alkaline phosphatase, increased gr1 | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | ALT increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 8 |
| other | ALT increased, gr1 | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Aspartate Aminotransferase Increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | AST increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Colitis | Gastrointestinal disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | decreased platelets | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
1 to 10 of 52Source ClinicalTrials.gov
See all 52 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 2 | 2 |
| Total, other adverse events | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 2 | 2 |
| Total, serious adverse events | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 2 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | SCHWARTZ, GARY K | CASE WESTERN RESERVE UNIVERSITY | NATIONAL CANCER INSTITUTE | 1987 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02383433
GET https://conductscience.org/api/trials/v1/NCT02383433/events?page=2